Shares rise and fall just on the orders of this agency, its heart fell on two stocks, disillusionment with one, know the names of the stocks

Goldman Sachs is such a global agency and brokerage firm, on whose every gesture the stock market acts. The stock whose rating is increased by this agency starts rising rapidly. On the contrary, if the rating of any stock is reduced, it starts falling. The same Goldman Sachs has recently advised to buy two shares and sell one share.

This brokerage has revised its target prices for Syngene International Ltd and Neuland Laboratories Ltd. Syngene’s target price has been increased by 20 percent to Rs 875, while Newland’s target price has been increased by 46 percent to Rs 9,100. On Friday, Syngene’s stock closed at Rs 749.05 on NSE, while Newland Labs’ stock closed at Rs 6,665.40. At the same time, brokerage firm Goldman Sachs has advised to sell Laurus Labs Ltd. The firm has said that this share will fall by 23 percent to Rs 350. Its closing rate on Friday was Rs 441.90.

Also read – This Tata Group company will give dividend of Rs 28 on one share, increase in profits

Possibility of triple profit
It is noteworthy that Goldman Sachs has recently expanded its coverage in the India CRO/CDMO sector. In view of this, Indian companies are becoming important in the global pharmaceutical supply chain. They expect India’s global market share to grow by 30bps in small CDMOs and 70bps in CRO by FY28. In the same scenario, this profit could triple.

Why are Syngene and Newland on the radar?
Syngene is the country’s largest integrated CRAMS/CRDMO, serving diverse sectors including pharmaceuticals, biotechnology and consumer goods. Goldman expects Syngene to significantly benefit from the China+1 trend due to its end-to-end service capabilities. Despite short-term macro challenges in CY24, several catalysts are expected, including improvement in biotech funding, ramp-up of manufacturing plants and securing new contracts. This becomes more important especially amid anti-China sentiment. Due to the implementation of the US Biosecure Act, the company can get much better profits.

Read this also – Three years ago the price was Rs 3, now it has crossed Rs 963, returns set the record high

Newland Labs manufactures APIs. With the changes in CDMO services, it has added a lot of new things to its offering. Despite growth challenges in FY25 due to high base, Goldman Sachs sees several opportunities for the company, including improvement in biotech funding, new capacity at Unit-3 starting late FY25 and commercialization of a large molecule in FY26/27 Is included. Passage of the US Biosecure Act may also provide significant benefits.

(Disclaimer: The stocks mentioned here are based on the advice of brokerage houses. If you want to invest money in any of these, then first consult a certified investment advisor. AyraNews24x7 will not be responsible for any profit or loss of yours. .)

,

Tag: tips to earn money, Share Market, Share Market, stock tips